Calidi Common Stock Shares Outstanding from 2010 to 2026
| CLDI Stock | 0.83 0.0006 0.07% |
Common Stock Shares Outstanding | First Reported 2010-12-31 | Previous Quarter 598 K | Current Value 655 K | Quarterly Volatility 1.3 M |
Check Calidi Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Calidi Biotherapeutics' main balance sheet or income statement drivers, such as Tax Provision of 13.6 K, Depreciation And Amortization of 1.9 M or Interest Expense of 1.2 M, as well as many indicators such as Price To Sales Ratio of 1 K, Dividend Yield of 0.14 or PTB Ratio of 5.65. Calidi financial statements analysis is a perfect complement when working with Calidi Biotherapeutics Valuation or Volatility modules.
Calidi | Common Stock Shares Outstanding | Build AI portfolio with Calidi Stock |
The Common Stock Shares Outstanding trend for Calidi Biotherapeutics offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Calidi Biotherapeutics is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Calidi Biotherapeutics' Common Stock Shares Outstanding Growth Pattern
Below is the plot of the Common Stock Shares Outstanding of Calidi Biotherapeutics over the last few years. It is the total number of shares of a company's common stock that are currently owned by all its shareholders. Calidi Biotherapeutics' Common Stock Shares Outstanding historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Calidi Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
| Common Stock Shares Outstanding | 10 Years Trend |
|
Common Stock Shares Outstanding |
| Timeline |
Calidi Common Stock Shares Outstanding Regression Statistics
| Arithmetic Mean | 2,067,616 | |
| Geometric Mean | 1,312,067 | |
| Coefficient Of Variation | 62.05 | |
| Mean Deviation | 1,181,045 | |
| Median | 2,980,241 | |
| Standard Deviation | 1,282,924 | |
| Sample Variance | 1.6T | |
| Range | 2.9M | |
| R-Value | (0.80) | |
| Mean Square Error | 623.5B | |
| R-Squared | 0.64 | |
| Significance | 0.0001 | |
| Slope | (204,010) | |
| Total Sum of Squares | 26.3T |
Calidi Common Stock Shares Outstanding History
About Calidi Biotherapeutics Financial Statements
Investors use fundamental indicators, such as Calidi Biotherapeutics' Common Stock Shares Outstanding, to determine how well the company is positioned to perform in the future. Although Calidi Biotherapeutics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 598 K | 655 K |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out the analysis of Calidi Biotherapeutics Correlation against competitors. For more detail on how to invest in Calidi Stock please use our How to Invest in Calidi Biotherapeutics guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is there potential for Biotechnology market expansion? Will Calidi introduce new products? Factors like these will boost the valuation of Calidi Biotherapeutics. Projected growth potential of Calidi fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Calidi Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Understanding Calidi Biotherapeutics requires distinguishing between market price and book value, where the latter reflects Calidi's accounting equity. The concept of intrinsic value - what Calidi Biotherapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Calidi Biotherapeutics' price substantially above or below its fundamental value.
It's important to distinguish between Calidi Biotherapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Calidi Biotherapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Calidi Biotherapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.